Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016

Dec 28 2016

• By Mandy Jackson

FDA approved background, 3D rendering, blue street sign

Related Content

Keeping Track: US FDA Approves Spinraza And Rubraca, Delays Ocrevus; Plus Submissions Galore

Dec 27 2016

Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy

Oct 07 2016

Filings Soon As Biogen Snaps Up Ionis' Antisense Treatment

Aug 02 2016

Biogen CEO Pick Vounatsos Suggests A Return To Commercial Focus

Dec 20 2016

Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales

Sep 23 2016

Biogen/Ionis’ Spinraza Data Shows Opportunity For Broad SMA Label

Nov 07 2016

AbbVie/United Therapeutics $350m Voucher Deal: Smart Move?

Aug 20 2015

Related Companies

Biogen, Inc.

Ionis Pharmaceuticals, Inc.

Sarepta Therapeutics, Inc.

AbbVie Inc.

United Therapeutics Corporation

GSK plc

Roche Holding AG

Additional Topics

Commercial Approvals Market Access Innovation Pediatrics Rare Diseases Reimbursement BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.